Captor Therapeutics stock reports a wider H1 loss

Published on 10/01/2026 at 05:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Captor Therapeutics stock posted a PLN 22.762 million H1 loss on September 15, 2026. Equity rose to PLN 65.1 million after new share issuance.

Captor Therapeutics, PLCPTRT00014, Illustration mit AI erstellt.

Captor Therapeutics stock reported a PLN 22.762 million net loss for the first half of 2026, compared with PLN 20.474 million a year earlier. The result, published on September 15, 2026, puts falling research revenue and financing needs at the center of the investment case.

H1 loss widens as revenue falls

According to Puls Biznesu on September 15, 2026, revenue from research and development services fell to PLN 1.962 million from PLN 4.616 million in the first half of 2025. The operating loss increased to PLN 24.189 million from PLN 21.461 million, while net loss per share widened to PLN 3.86 from PLN 3.70.

The comparison is mixed rather than uniformly negative. Gross profit from services increased to PLN 1.789 million from PLN 1.150 million, as the cost of services fell to PLN 173,000 from PLN 3.466 million. That improvement did not offset higher research and development spending and lower collaboration revenue.

Capital strengthens the balance sheet

According to Quartr on September 15, 2026, equity reached PLN 65.065 million at the end of June, up from PLN 23.481 million at the end of 2025. The increase followed a March share issue that raised PLN 65.6 million and lifted the share count to 6,353,397.

Cash flow remains a key counterweight. Operating cash flow was negative PLN 24.628 million in the first half, compared with positive PLN 12.464 million in the prior-year period. Management said its resources should cover at least 12 months, while partnership discussions for NEK7 degraders and other projects could provide additional funding, Quartr reported.

November date sets next checkpoint

The next scheduled results publication is November 19, 2026, for the third quarter, according to Zonebourse. That report will show whether collaboration revenue improves after the weak first half and whether the March financing is translating into additional development progress.

Captor Therapeutics shares trade on the Warsaw Stock Exchange under CTX. As of September 30, 2026, the stock had a PLN 37.20 to PLN 89.20 52-week range and a market capitalization of PLN 440.8 million. The company is classified in biotechnology and medical research, leaving clinical progress and partnership execution as the main variables behind the valuation.